Moreover, in November last year, bluebird completed a spin-off of its oncology programs and portfolio into an independent, publicly-traded company, 2seventy bio, Inc. TSVT, transferring Bristol Myers BMY Abecma to 2seventy bio in the process. The separation was intended to help bluebird focus extensively on its gene therapy pipeline for severe genetic diseases.